A new one-time treatment for high cholesterol has shown promise in reducing heart attack risk for life, potentially offering an alternative to statins. The treatment, which involves gene editing, has been found to lower bad cholesterol levels, although its effects and implications are still being studied. It is unclear how this development will impact current guidelines for cholesterol management, which may already be due for an update to address emerging concerns about cholesterol.